

SP26 Declarations of interest by the authors of other submissions to the panel

[Others are contained within their submissions in SP25]

George Davey Smith

I declare that that I have read and understood the BMJ Group policy on declarations of interest. I hereby declare the following interests, according to the policy.

I have the following interests to declare:

Personal

I have twice received travel expenses and an honorarium from Merck, Sharpe and Dome (MSD) for speaking at meetings on genetics.

Organisational

Pfizer fund two research associates in an unrestricted award for epigenomic research in the MRC unit in which I work.

Unpaid positions (current)

Name: George Davey Smith



Signature

Date: 30th May 2014

Bernard J Gersh

I declare that that I have read and understood the BMJ Group policy on declarations of interest. I hereby declare the following interests, according to the policy.

I have the following interests to declare:

Personal

Steering Committee Member for Medtronic, Inc
Member of Data Safety Monitoring Board for Baxter Healthcare Corporation
Member of Data Safety Monitoring Board for Cardiovascular Research Foundation
Consulting, Merck & Company
Member of Data Safety Monitoring Board for St. Jude Medical, Inc
Member of Executive Committee for Ortho-McNeil Janssen Scientific Affairs
Chairman of Data Safety Monitoring Board for TEVA Pharmaceuticals
Member of Data Safety Monitoring Board for Boston Scientific

Organisational

Unpaid positions (current)

Name: Bernard J. Gersh, MBChB

Date: July 14, 2014

Aldo Maggioni

I declare that that I have read and understood the BMJ Group policy on declarations of interest. I hereby declare the following interests, according to the policy.

I have the following interests to declare:

Personal

Dr Aldo Pietro Maggioni is member of the Executive/Steering Committee of studies sponsored by Bayer, Cardiorientis, Novartis, Pfizer, Abbott Vascular.

Organisational

The GISSI group received an unrestricted grant of research to conduct the study from AstraZeneca, SPA, Pfizer, Sigma Tau. The study ended in 2008.

Unpaid positions (current)

Member of the Steering Committee of studies conducted by the Oxford University, PHRI.

Name: Aldo Pietro Maggioni

Signature



Date: May 24, 2014

Connie Newman

I declare that that I have read and understood the BMJ Group policy on declarations of interest. I hereby declare the following interests, according to the policy.

© I have the following interests to declare:

Personal

I own a small amount of Pfizer stock, valued at approximately \$6,000 (equivalent to about 3,600 pounds).

Organisational

Not applicable

Unpaid positions (current)

Member of the Cholesterol Treatment Trialists' Collaboration

Name: Connie Newman, M.D.



Date: May 24, 2014

David Preiss

I declare that that I have read and understood the BMJ Group policy on declarations of interest. I hereby declare the following interests, according to the policy.

I have the following interests to declare:

Personal

- No personal declarations of relevance to statins and/or statin producing companies
- I have twice participated in advisory boards for Sanofi regarding PCSK9 inhibitor therapy (£900 each)

Organisational

- The Scottish Lipid Forum, of which I am co-chairperson (since 2013-present), holds an annual overnight meeting. This was fully sponsored by AstraZeneca and Merck in 2013. This year's meeting will be fully sponsored by these two companies and also Sanofi. No participant (attendee or speaker) received personal payment but overnight accommodation and board are covered by the sponsorship.
- Current UK national co-ordinator + local PI for GAUSS-3 trial of PCSK9 inhibitor therapy in patients with confirmed statin intolerance (Amgen) and local PI for SPIRE 1 and 2 trials of PCSK9 inhibitor therapy (Pfizer)

Unpaid positions (current)

- HEART UK member; HEART UK Familial Hypercholesterolaemia Implementation Team member for Scotland
- On SIGN guideline committee for upcoming revision of cardiovascular guideline
- Co-chairperson of the Scottish Lipid Forum
- Due to become SHARP (Scottish Heart and Arterial Disease Risk Prevention) trustee
- Lead / joint lead on research publications in 2010 (Lancet), 2011 (JAMA), 2012 (JAMA) regarding risk of new-onset diabetes and pancreatitis on statins, based on trial data

Name: David Preiss

Date: 23 May 2014

Naveed Sattar

I declare that that I have read and understood the BMJ Group policy on declarations of interest. I hereby declare the following interests, according to the policy.

I have the following interests to declare:

Personal

- I have attended advisory boards for Amgen £900 twice in UK and for £3000 in USA in last 3 years and have one more advisory board to come in October in USA
- I have attended advisory boards for Sanofi in Paris for 3000 euros in 2013

Both companies – Amgen and Sanofi - are trialling PCSK9 inhibitors which are not currently marketed for lipid-lowering.

Organisational

- I was on editorial board for Joint British Societies 3 recommendations on JBS3 Board for prevention of CVD: reference to document: Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014 Apr;100 Suppl 2:ii1-ii67. doi: 10.1136/heartjnl-2014-305693. Review. PubMed PMID: 24667225..

- Current PI for GAUSS-3 trial of PCSK9 inhibitor therapy in patients with confirmed statin intolerance (Amgen)
- I was senior author on paper assessing the statin-diabetes link for National Lipid Association – this task force paper has now been published. I was paid \$1000 for my time in helping preparing this document by NLA and this included a meeting in Atlanta, USA; Ref: Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S17-29. doi: 10.1016/j.jacl.2014.02.012. PubMed PMID: 24793439.

Unpaid positions (current)

- Chair of SIGN guideline committee for upcoming revision of cardiovascular guideline on CVD prevention
- Lead / joint senior author on research publications in 2010 (Lancet), 2011 (JAMA), 2012 (JAMA) regarding risk of new-onset diabetes and pancreatitis on statins, based on trial data

I have **not** signed any contracts in which I to be paid for advocating the opinion of that organisation or company and never intend to do so.

Name: Naveed Sattar

Date: 26th May 2014

Peter Sever

I declare that that I have read and understood the BMJ Group policy on declarations of interest. I hereby declare the following interests, according to the policy.

© I have the following interests to declare:

Personal

Consultant for Pfizer Inc
Honoraria for lectures Pfizer Inc

Organisational

Imperial College Receipt of grant income for ASCOT Study

Unpaid positions (current)

Nil

Name: Professor Peter Sever

Date: May 27th 2014

